Central retinal vein occlusion: a review
- PMID: 22003973
- DOI: 10.1111/j.1442-9071.2011.02713.x
Central retinal vein occlusion: a review
Abstract
Central retinal vein occlusion remains a common cause of unilateral visual loss. Until recently, our treatment options for this condition were limited only to laser photocoagulation for the devastating end sequelae of anterior segment neovascularization. Over the last 2 years, a number of randomized controlled trials have given us significant new treatment options to address not only visual loss from macular oedema but also the ability to create a bypass around the obstruction in the central retinal vein and to address the raised venous hydrostatic pressure. In the future, it is likely that combination approaches to the management of central retinal vein occlusion will develop using specific agents and techniques to address the components of macular oedema, retinal ischaemia and raised venous hydrostatic pressure, all of which combine to produce the clinical picture and the reduction in vision seen in this condition.
© 2011 The Author. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists.
Similar articles
-
Managing retinal vein occlusion.BMJ. 2012 Feb 22;344:e499. doi: 10.1136/bmj.e499. BMJ. 2012. PMID: 22362114 Review. No abstract available.
-
Ranibizumab and retinal vein occlusion. Too many outstanding questions.Prescrire Int. 2012 Sep;21(130):207. Prescrire Int. 2012. PMID: 23016250
-
Branch retinal vein occlusion: clinical findings, natural history, and management.Compr Ophthalmol Update. 2006 Nov-Dec;7(6):265-76. Compr Ophthalmol Update. 2006. PMID: 17244442 Review.
-
Management of macular edema associated with retinal vein occlusion.Arch Ophthalmol. 2012 Oct;130(10):1314-6. doi: 10.1001/archophthalmol.2012.2462. Arch Ophthalmol. 2012. PMID: 23044946 No abstract available.
-
Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial.Acta Ophthalmol. 2015 Feb;93(1):e29-37. doi: 10.1111/aos.12488. Epub 2014 Jul 8. Acta Ophthalmol. 2015. PMID: 25042729 Clinical Trial.
Cited by
-
Hypermixed Convolutional Neural Network for Retinal Vein Occlusion Classification.Dis Markers. 2022 Nov 11;2022:1730501. doi: 10.1155/2022/1730501. eCollection 2022. Dis Markers. 2022. PMID: 36408465 Free PMC article.
-
Evaluation of lamina cribrosa thickness in patients diagnosed with central retinal vein occlusion.Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2087-2093. doi: 10.1007/s00417-019-04401-3. Epub 2019 Jul 3. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31267221
-
Central retinal vein occlusion and pseudoexfoliation syndrome.Clin Interv Aging. 2015 May 20;10:879-83. doi: 10.2147/CIA.S77630. eCollection 2015. Clin Interv Aging. 2015. PMID: 26056437 Free PMC article.
-
Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review.Front Med (Lausanne). 2024 Jun 20;11:1362108. doi: 10.3389/fmed.2024.1362108. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38966527 Free PMC article. Review.
-
Assessment of Aptamer as a Potential Drug Targeted Delivery for Retinal Angiogenesis Inhibition.Pharmaceuticals (Basel). 2023 May 16;16(5):751. doi: 10.3390/ph16050751. Pharmaceuticals (Basel). 2023. PMID: 37242534 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources